Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress

Arrowhead Pharma’s REDEMPLO Authorized In EU; Now Prescribable And Reimbursable In Germany For Familial Chylomicronaemia Syndrome

REDEMPLO® (plozasiran) is listed in the Lauer-Taxe® database as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS), diagnosed either based on clinical

HC Wainwright & Co. Maintains Buy on Arrowhead Pharma, Raises Price Target to $120

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $115 to $120.

Arrowhead Pharma Q3 EPS $(1.36) Misses $(1.32) Estimate, Sales $75.253M Beat $54.294M Estimate

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.32) by 3.03 percent. This is a 7.94 percent decrease over losses of $(1.26) per share from

Why Is Biohaven Stock Soaring Wednesday?

Biohaven gains $795M in global licensing deal and $4M lawsuit win. BHVN jumps 13% as William Blair eyes upcoming trial data.

Biohaven shares are trading higher after the company announced that the U.S. District Court for the District of Delaware ruled in its favor in the case against Avilar Therapeutics. Biohaven announced a collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to the company's Kv7 ion channel platform.